Question 1

What are the potential side effects of lorlatinib and ramucirumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific eligibility requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer clinical trial (NCT06007937). Contact the study team or your healthcare provider for specific answers.

What this study is about